Physician profile
Thomas Rosvanis
NPI 1093710048
$12,197.95
in general payments reported to CMS, 2019-2025
44 companies · $1,530 in 2025
The $1,530 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,481 · 2020: $1,069 · 2021: $1,432 · 2022: $2,676 · 2023: $1,966 · 2024: $2,043 · 2025: $1,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,524 · Travel and Lodging: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,524.36 |
| Travel and Lodging | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,368.49 | 2019-2025 | Erleada |
| Astellas Pharma US INC | $1,351.40 | 2019-2024 | Myrbetriq, Xtandi, Veozah |
| Sumitomo Pharma America, INC. | $1,340.77 | 2023-2025 | Orgovyx, Gemtesa |
| Boston Scientific Corporation | $1,161.48 | 2019-2025 | Solyx Sis System, Ams 700, Axonics |
| Dendreon Pharmaceuticals LLC | $1,022.69 | 2019-2025 | Provenge |
| Axonics, INC. | $536.69 | 2020-2024 | Axonics, Bulkamid |
| Bayer Healthcare Pharmaceuticals INC. | $528.69 | 2019-2025 | |
| Coloplast Corp | $461.07 | 2019-2025 | Speedicath |
| Myovant Sciences INC. | $431.44 | 2021-2022 | |
| Pfizer INC. | $423.77 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $356.62 | 2020-2025 | Lynparza |
| Myriad Genetic Laboratories, INC. | $329.87 | 2020-2023 | Prolaris, Precisetumor |
| Abbvie INC. | $236.33 | 2019-2025 | Lupron Depot |
| Agiliti Surgical, INC. | $216.02 | 2023-2025 | Koelis Trinity Mri/US Fusion, Sonablate Hifu, Sonablate |
| Olympus America INC. | $210.85 | 2019-2025 | Itind System, Olympus |
Show all 43 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$397.44 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Rosvanis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.